<code id='38B223BA62'></code><style id='38B223BA62'></style>
    • <acronym id='38B223BA62'></acronym>
      <center id='38B223BA62'><center id='38B223BA62'><tfoot id='38B223BA62'></tfoot></center><abbr id='38B223BA62'><dir id='38B223BA62'><tfoot id='38B223BA62'></tfoot><noframes id='38B223BA62'>

    • <optgroup id='38B223BA62'><strike id='38B223BA62'><sup id='38B223BA62'></sup></strike><code id='38B223BA62'></code></optgroup>
        1. <b id='38B223BA62'><label id='38B223BA62'><select id='38B223BA62'><dt id='38B223BA62'><span id='38B223BA62'></span></dt></select></label></b><u id='38B223BA62'></u>
          <i id='38B223BA62'><strike id='38B223BA62'><tt id='38B223BA62'><pre id='38B223BA62'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:knowledge    Page View:998
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In